Markus Magerl
As seen in:
Allergy - European Journal of Allergy and Clinical Immunology,
Color Research & Application,
Wiley Online Library,
Clinical and Translational Allergy,
World Allergy Organization Journal,
The Lancet,
HCP Live,
The Journal of Allergy & Clinical Immunology,
EMJ- European Medical Journal,
Value in Health Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Markus Magerl
PCR66 LONG-TERM PROPHYLACTIC TREATMENT WITH ORAL DEUCRICTIBANT IMPROVED DISEASE CONTROL AND HEALTH-RELATED QUALITY OF LIFE IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA: FINAL RESULTS OF THE CHAPTER-1 OPEN-LABEL EXTENSION STUDY
1Allergy, Asthma and Immunology Associates, Ltd., Scottsdale, AZ, USA 2AllerVie Health, Clinical Research Center of Alabama, Birmingham, AL, USA 3AOR Villa Sofia-Cervello, UOC di Patologia Clinica e Immunologia, Palermo, Italy 4Azienda Ospedale Università di Padova, Padua, Italy 5CHU de Montréal, Université de Montréal, Montréal, QC, Canada 6St. James's Hospital and Trinity College, Wellcome Trust CRF, Dublin, Ireland 7University Hospital Southampton NHS Foundation Trust, Southampton, United...
HAE in 2026: New Therapies, Updated Guidelines, the Case for Early Treatment
The treatment landscape for hereditary angioedema is undergoing one of its most significant evolutions in years. Updated international guidelines, pivotal phase 3 data, and promising early-phase results are collectively reshaping how clinicians approach both prophylaxis and acute management of this rare, potentially life-threatening condition. Three experts recently spoke with HCPLive about where the field stands and where it is headed.
BW-20805 Reduces HAE Attacks in Phase 2 Trial, With Markus Magerl, MD
Late-breaking data presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in Philadelphia suggest that BW-20805, an investigational therapy designed to suppress plasma prekallikrein production through a targeted RNA interference approach, may offer long-acting prophylaxis for patients with hereditary angioedema (HAE).
Algorithms in Allergy: Hereditary Angioedema
ACARE Angioedema Centers of Reference and Excellence ANGPT-1 gene encoding angiopoietin-1 C1INH C1-inhibitor CPN1 gene encoding carboxypeptidase N DAB2IP gene encoding disabled homolog 2-interacting protein F12 gene encoding coagulation factor XII FXII coagulation factor XII HAE hereditary angioedema HAE-C1INH hereditary angioedema due to C1-inhibitor deficiency HAE-FXII hereditary angioedema due to F12 mutations HAE-nC1INH hereditary angioedema with normal C1-inhibitor HAE-PLG hereditary...
Algorithms in Allergy: Hereditary Angioedema
ACARE Angioedema Centers of Reference and Excellence ANGPT-1 gene encoding angiopoietin-1 C1INH C1-inhibitor CPN1 gene encoding carboxypeptidase N DAB2IP gene encoding disabled homolog 2-interacting protein F12 gene encoding coagulation factor XII FXII coagulation factor XII HAE hereditary angioedema HAE-C1INH hereditary angioedema due to C1-inhibitor deficiency HAE-FXII hereditary angioedema due to F12 mutations HAE-nC1INH hereditary angioedema with normal C1-inhibitor HAE-PLG hereditary...
Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study
1 INTRODUCTION Hereditary angioedema (HAE) describes an autosomal dominant inherited disease that is primarily characterized by the irregular occurrence of local edema lasting for up to 7 days.
Berotralstat Improved Quality of Life through 96 Weeks Across Multiple Subgroups of Patients with Hereditary Angioedema
Berotralstat is a first-line, once-daily (QD) oral prophylaxis for hereditary angioedema (HAE) shown to reduce the burden of disease and treatment. We present patient-reported quality of life (QoL) in patients who received berotralstat in APeX-2 (NCT03485911).
Efficacy and Safety of Subcutaneous Garadacimab for the Prophylaxis of Hereditary Angioedema Attacks in Adults and Adolescent Patients with HAE: Results from a Multicenter, Placebo-Controlled Phase 3 Trial
The efficacy and safety of garadacimab, a fully human immunoglobulin G4 monoclonal antibody targeting activated factor XII for the prevention of hereditary angioedema (HAE) attacks, were evaluated in a randomized, placebo-controlled, 6-month, Phase 3 trial (NCT04656418).
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial
Summary Background Hereditary angioedema is associated with dysregulation of the kallikrein–kinin system. Factor XII (FXII) is a key initiator of the kallikrein–kinin system, which produces bradykinin, a central mediator of angioedema. Garadacimab (CSL Behring) is a first-in-class, fully human, immunoglobulin G4 monoclonal antibody targeting activated FXII, intended to prevent attacks in patients with C1-esterase inhibitor-deficient hereditary angioedema (HAE-C1-INH).
Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
Abstract Background An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health‐related quality of life (HRQoL) in patients with hereditary angioedema (HAE). Methods Patients with HAE‐1/2 received either lanadelumab 150 mg every 4 weeks (q4wks; n = 28), 300 mg q4wks (n = 29), 300 mg every 2 weeks (q2wks; n = 27), or placebo (n = 41) for 26 weeks (days 0–182).
Development of the Angioedema Control Test (AECT) ‐ a patient reported outcome measure that assesses disease control in patients with recurrent angioedema
ORIGINAL ARTICLE: ATOPIC DERMATITIS, URTICARIA AND SKIN DISEASE Karsten Weller Corresponding Author E-mail address: karsten.weller@charite.de https://orcid.org/0000-0003-4437-0313 Allergie‐Centrum‐Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, Germany Corresponding Author: PD Dr. med.
Disease activity and stress are linked in a subpopulation of chronic spontaneous urticaria patients - Schut - - Allergy - Wiley Online Library
Letter to the Editor Disease activity and stress are linked in a subpopulation of chronic spontaneous urticaria patients Eva Milena Johanne Peters Corresponding Author E-mail address: eva.peters@eva-peters.com CharitéCentrum 12 for Internal Medicine and Dermatology, Department of Psychosomatic Medicine and Psychotherapy, Charité‐Universitätsmedizin Berlin, Germany Psychoneuroimmunology Laboratory, Department of Psychosomatic Medicine and Psychotherapy, Justus‐Liebig‐University, Gießen,...
Diagnosis and Treatment of Chronic Inducible Urticaria
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. News & Views: Algorithms in Allergy and Clinical Immunology Diagnosis and Treatment of Chronic Inducible Urticaria Marcus Maurer Corresponding Author E-mail address: marcus.maurer@charite.de Allergie‐Centrum‐Charité, Dept. of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Germany Corresponding author: Marcus Maurer, MD Dept.
Diagnosis and treatment of chronic inducible urticaria - Maurer - - Allergy - Wiley Online Library
NEWS & VIEWS: ALGORITHMS IN ALLERGY AND CLINICAL IMMUNOLOGY Diagnosis and treatment of chronic inducible urticaria Marcus Maurer Corresponding Author E-mail address: marcus.maurer@charite.de https://orcid.org/0000-0002-4121-481X Department of Dermatology and Allergy, Allergie‐Centrum‐Charité, Charité – Universitätsmedizin Berlin, Berlin, Germany Correspondence Marcus Maurer, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany.
Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
Andrea Zanichelli1Email author, Markus Magerl2, Hilary J. Longhurst3, 10, Werner Aberer4, Teresa Caballero5, Laurence Bouillet6, Anette Bygum7, Anete S.
The international WAO/EAACI guideline for the management of hereditary angioedema - the 2017 revision and update
Hereditary angioedema (HAE) is a rare disease and a serious health problem, globally and for affected patients and their families. The pathophysiological background is primarily a vascular reaction to an overshooting local production of bradykinin. Evidence-based recommendations are needed to inform and guide clinical decision makers. This is the first revision and update of the global guideline for the diagnosis and management of HAE [1].
Hereditary Angioedema: The Dawn of a New Era of Hereditary Angioedema Management
In the current treatment landscape for on-demand treatment of HAE there are a number of options, such as intravenous plasma-derived C1-INH (C1-INH[IV]), recombinant human C1-INH, icatibant (a bradykinin B2-receptor antagonist), and ecallantide (a kallikrein inhibitor). However, prophylactic treatment options are very limited, with only androgens, tranexamic acid, and plasma-derived C1-INH(IV) concentrate available.
Prophylaxis of HAE Attacks: A Randomized Trial of Oral Plasma Kallikrein Inhibition with Avoralstat
Publication HistoryPublished Online: May 11, 2016Accepted: March 15, 2016; Received in revised form: February 29, 2016; Received: November 3, 2015;
The Angioedema Quality of Life Questionnaire (AE-QoL) - Assessment of Sensitivity to Change and Minimal Clinically Important Difference
Recurrent angioedema patients with chronic spontaneous urticaria or hereditary angioedema were repeatedly asked to complete the AE-QoL along with the SF-12 and other anchors for QoL impairment and disease activity during routine care visits. The sensitivity to change of AE-QoL was determined by correlating changes in its scores over time with changes in the applied anchors. In addition, the MCID was determined by using anchor-based and distributional criterion-based approaches.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Markus
Contact Markus, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack